Core Viewpoint - The company Hansai Aitai-B (03378) has received approval from the National Medical Products Administration of China to conduct clinical trials for its innovative drug HX111, which is a first-in-class OX40-targeted antibody-drug conjugate (ADC) [1][4]. Group 1: Stock Performance - The stock price of Hansai Aitai-B increased by nearly 6% during trading, with a current price of 17.60 HKD, reflecting a 2.33% rise and a trading volume of 16.8885 million HKD [1][4]. Group 2: Product Development - HX111 is identified as a first-in-class OX40-targeted ADC, with preclinical studies indicating that OX40 is overexpressed in several malignant tumors compared to normal tissues, making it a suitable target for ADC [1][4]. - HX111 is the third first-in-class molecule to advance to clinical development, following the company's previous dual-specific antibody therapies HX009 and HX044 [1][4]. - The company aims to continue its efforts in clinical development to bring more innovative first-in-class drugs to market [1][4].
翰思艾泰-B盘中涨近6% 创新药HX111获得国家药监局批准临床试验